A method and system for the treatment of honey bees (Apis mellifera), bats, and butterflies protects them from various life threatening conditions, including Colony Collapse Disorder and in particular, provides honey bees with the ability to assimilate and degrade pesticides such as neonicotinoids and fipronil.

Provided herein, inter alia, are compositions of short chain fatty acid (SCFA)-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

Provided herein, inter alia, are compositions of short chain fatty acid (SCFA)-producing microorganisms and methods of making and using the same to inhibit pathogenic bacterial populations in the gastrointestinal tracts of an animal and additionally promote improvement of one or more metrics in an animal, such as increased bodyweight gain, decreased feed conversion ratio (FCR), improved gut barrier integrity, reduced mortality, reduced pathogen infection, and reduced pathogen shedding in feces.

Methods to increase viability and revivability of bacteria compared to their wild type counterparts, are disclosed herein. New strains of an anerobic bacteria is also disclosed obtained by the methods described herein. Further, disclosed are compositions comprising these bacteria as well as methods of treatment including the use of the bacteria described.

Methods to increase viability and revivability of bacteria compared to their wild type counterparts, are disclosed herein. New strains of an anerobic bacteria is also disclosed obtained by the methods described herein. Further, disclosed are compositions comprising these bacteria as well as methods of treatment including the use of the bacteria described.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

A method for treating the gastro-intestinal or a urogenital system of a subject with prebiotic nutrients and probiotic bacteria is provided. Multi-chamber products are described which include at least two chambers wherein probiotic bacteria or human microbiome transplants are contained in one or more inner chambers and wherein prebiotic nutrients are contained in an outer chamber, the outer chamber completely enclosing the inner chamber(s). One or both chambers may contain a pharmaceutically acceptable material that is solid outside the human body when in a dry environment, but that melts at internal body temperature. The products may be administered by oral, rectal, vaginal, or urethral routes.

The disclosure provides methods and compositions for the preservation of bacteria. Aspects of the present disclosure provide methods of preparing a preserved bacterial composition comprising flash freezing a bacterial composition and lyophilizing the flash frozen bacterial composition to produce a preserved bacterial composition. In some embodiments, the bacterial composition comprises one or more bacterial strains. In some embodiments, the one or more bacterial strains comprise one or more anaerobic bacterial strains. In some embodiments, the anaerobic bacterial strains are strict anaerobic bacteria.

The present disclosure provides technologies for modulating microbiome of mammalian subjects (e.g., human subjects). The present disclosure, among others, provides therapeutic compositions and methods of using the same, wherein the therapeutic compositions comprising an engineered population of therapeutic bacteria that (i) are non-pathogenic and commensal in a subject to be administered; and (ii) are resistant to one or more target bacteriophages. In some embodiments, such therapeutic compositions can be useful for treatment of subjects suffering from or susceptible to a microbiome-dysfunction-associated disease, disorder, or condition (e.g., inflammatory bowel disease).

The present disclosure provides technologies for modulating microbiome of mammalian subjects (e.g., human subjects). The present disclosure, among others, provides therapeutic compositions and methods of using the same, wherein the therapeutic compositions comprising an engineered population of therapeutic bacteria that (i) are non-pathogenic and commensal in a subject to be administered; and (ii) are resistant to one or more target bacteriophages. In some embodiments, such therapeutic compositions can be useful for treatment of subjects suffering from or susceptible to a microbiome-dysfunction-associated disease, disorder, or condition (e.g., inflammatory bowel disease).